Alfuzosin (Alfuzosinum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Alpha-blockers

Included in the formulation
  • Alfuzosin
    pills inwards 
    VERTEKS, AO     Russia
  • Alfuprost® MR
    pills inwards 
    Ranbaxy Laboratories Limited     India
  • Alfuzosin
    pills inwards 
    PHARMSTANDART-FORESTRY, OJSC     Russia
  • Dalfaz® retard
    pills inwards 
    Sanofi Winthrop Industry     France
  • Dalfaz® SR
    pills inwards 
    Sanofi Winthrop Industry     France
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    G.04.C   Drugs for the treatment of benign prostatic hyperplasia

    Pharmacodynamics:

    The alpha-blocker acting mainly on postsynaptic α1-adrenergic receptors. Blocking α1-adrenergic receptors located in the triangle and sphincter of the bladder, urethra, alfuzosin eliminates spasm of smooth muscle fibers, which leads to a decrease in the resistance of urine outflow. Reduces the tone of the smooth muscles of the arteries and veins. Reduces OPSS and systemic blood pressure.

    Pharmacokinetics:

    It is absorbed from the digestive tract. Cmax in blood plasma is achieved after 3 hours and is 10.3 ng / ml. Differences in maximum and minimum plasma concentrations are negligible. Eating does not affect suction. Patients over 75 years of age have a higher plasma concentration and bioavailability of alfuzosin (possibly due to a decrease in metabolism in the liver).In patients with severe renal dysfunction, an increase in alfuzosin clearance is possible (possibly due to less binding to plasma proteins).

    Indications:

    Treatment of functional manifestations of benign prostatic hyperplasia in the absence of surgical intervention, as well as in cases of progressive growth, especially in elderly patients.

    ICD-10

    XIV.N40-N51.N40   Hyperplasia of the prostate

    Contraindications:

    Hypersensitivity to alfuzosin. With caution: IHD, angina pectoris, concomitant therapy with antihypertensive drugs, age over 75 years.

    Carefully:

    IHD, angina pectoris (the possibility of frequent and heavier angina attacks), concomitant therapy with antihypertensive drugs, age over 75 years.

    Patients receiving antihypertensive drugs may develop orthostatic hypotension within a few hours after taking alfuzosin with typical clinical symptoms (dizziness, severe weakness, cold perspiration) or without it. Orthostatic hypotension is usually transient and is usually seen at the beginning of the drug and usually does not require withdrawaltreatment. At occurrence of these phenomena the patient should be in a horizontal position before their full disappearance. Before starting treatment, the patient should be warned about the possibility of orthostatic hypotension.

    Caution should be exercised to patients with a history of a pronounced hypotensive response in response to other alpha1- adrenoblokatorov - need a more thorough control of blood pressure, including. when moving from horizontal to vertical position, especially at the beginning of treatment.

    In patients with IHD, antianginal therapy should continue. With the resumption or weighting of angina, treatment with alfuzosin should be discontinued.

    It should be taken into account (especially at the beginning of treatment) the possibility of developing dizziness and asthenic conditions, which can affect the ability to drive vehicles and work with mechanisms.

    Pregnancy and lactation:The drug is contraindicated for use in pregnancy and lactation.
    Dosing and Administration:

    Inside - for 2.5 mg 3 times / day. For patients older than 65 years - the initial dose is 2.5 mg 2 times / day (morning and evening); in the future, the dose may be increased (but not more than 10 mg / day).

    Side effects:

    From the digestive system: pain in epigastrium, nausea, diarrhea; From the side of the central nervous system: dizziness, headache; rarely - drowsiness. From the cardiovascular system: rarely - tachycardia, orthostatic hypotension. Allergic reactions: rarely - skin rash, itching. Other: malaise; rarely - swelling, pain behind the sternum.

    Overdose:Treatment is symptomatic.
    Interaction:

    Alflusozin nIt is incompatible with other alpha1-adrenoblockers.

    With simultaneous use of alfuzosin with antihypertensive agents (especially calcium channel blockers), a marked decrease in blood pressure is possible, up to the development of collapse.

    With the simultaneous use of alfuzosin with funds for general anesthesia, the development of instability of blood pressure during anesthesia is likely.

    Special instructions:

    Use with caution in patients with IHD, angina pectoris. If there is a worsening of the course (increased frequency and weight of attacks) of angina pectoris, alfuzosin should be canceled.

    Use with caution in patients older than 75 years and patients with severe renal dysfunction.

    Instructions
    Up